Cachexia

Clinical Data Published at ASCO Support the Potential of VIVUS’ PANCREAZE® to Stabilize Weight and Improve Gastrointestinal Outputs in Patients with Pancreatic Cancer

Retrieved on: 
torsdag, maj 30, 2024
PERT, MPH, Patient, PDAC, SOC, Anemia, Gastrointestinal tract, Bromelain, Clinical trial, Cachexia, Safety, Serum, Cancer, Argyreia nervosa, Pancreatic cancer, Abstract, Steatorrhea, ASCO, Cedars-Sinai Medical Center, Associate, Exocrine pancreatic insufficiency, Society, Weight loss, Cystic fibrosis, Malnutrition, Quality of life, Standard of care, Annual general meeting, Chronic pancreatitis, Pharmaceutical industry

The data also suggest that PANCREAZE may reduce stool frequency and improve stool consistency.

Key Points: 
  • The data also suggest that PANCREAZE may reduce stool frequency and improve stool consistency.
  • VIVUS provided PANCREAZE and funding to support the clinical trial.
  • PANCREAZE is approved in the United States and Canada for the treatment of EPI due to cystic fibrosis or other conditions.
  • The data was published in an ePoster at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4, 2024, in Chicago, IL and online.

Veru Announces Steven B. Heymsfield M.D. as the Principal Investigator for its Enobosarm Phase 2b Clinical Trial for High Quality Weight Loss

Retrieved on: 
onsdag, maj 15, 2024
Pharmacology, Body, Principal, Patient, Metabolism, Merck & Co., Agonal respiration, Route of administration, Facial muscles, The Obesity Society, ASN, Obesity, ASPEN, FDA, Cachexia, Ephedra, MD, Assistant, Surgeon, Research, Feeding tube, Emory University, Medicine, Physician, Body composition, Merck, Associate, Professor, Columbia University, Society, Science, Weight loss, Malnutrition, Pennington Biomedical Research Center, NIH, Medical device

As the Principal Investigator for the Company’s enobosarm Phase 2b clinical trial, Dr. Heymsfield will lead the clinical trial sites.

Key Points: 
  • As the Principal Investigator for the Company’s enobosarm Phase 2b clinical trial, Dr. Heymsfield will lead the clinical trial sites.
  • “I am pleased to serve as the Principal Investigator for this important Phase 2b enobosarm clinical trial.
  • "Dr. Heymsfield is an expert in body composition and obesity and an ideal clinical leader to serve as the Principal Investigator of the enobosarm Phase 2b clinical trial," said Mitchell Steiner, M.D., Chairman, President, and Chief Executive Officer of Veru Inc. “Veru is proud to have Dr. Heymsfield as our partner with the enobosarm clinical trial.
  • We look forward to enrolling this Phase 2b clinical trial expeditiously with data expected by year-end."

Mitigating Muscle Loss Becoming More Vital, Global Cancer Cachexia Market Projected to Reach $3.3 Billion in 2024

Retrieved on: 
onsdag, maj 8, 2024
MSD, PFS, FDA, Pfizer, MRNA, News, Atrophy, Weight loss, Doctor of Philosophy, Vaccine, University of Toronto, PFE, Medicinal chemistry, Medicine, Genome, Moderna, Diagnosis, AstraZeneca, Prevalence, GEJ, University, CPS, HER2, Food, OTC, IHC, Cachexia, Pneumococcal conjugate vaccine, Messenger, Quality of life, RSV, Patient, Facial muscles, Professor, Oncology, Trastuzumab, Research, Incidence, Fatigue, EPS, Neoplasm, MUSL, MRK, Tafamidis, Progression-free survival, PALM, PD-L1, COVID-19, Growth, Pharmaceutical industry

Cachexia is a medical condition known as ‘wasting syndrome’ that causes severe weight loss, muscle loss, and loss of body fats.

Key Points: 
  • Cachexia is a medical condition known as ‘wasting syndrome’ that causes severe weight loss, muscle loss, and loss of body fats.
  • The Cancer Cachexia market refers to the segment of the healthcare industry focused on addressing the multifaceted challenges associated with cachexia in cancer patients.
  • A report from Custom Market Insights projects that the global Cancer Cachexia Market is expected to record a CAGR of 5.1% from 2024 to 2033.
  • In 2024, the market size is projected to reach a valuation of USD 3.3 Billion.

Baseline Enrollment Completed for AMRA Medical and Linköping University’s Landmark Liver Disease Study

Retrieved on: 
torsdag, april 25, 2024
Surgery, Medical Devices, Hospitals, Science, Fitness & Nutrition, Clinical Trials, Cardiology, Diabetes, Biotechnology, Health, Health Technology, Research, University, Education, Radiology, Pharmaceutical, Oncology, Mortality, Social stigma, Gastroenterology, Liver disease, Contraindication, MFI, Cachexia, Hepatocellular carcinoma, BioMed Central, Body composition, Patient, HMV, Medicine, Fatty liver disease, Cirrhosis, MRI, Public health surveillance, Multimedia, Diagnosis, Manuscript, Biomarker, Portal hypertension, Quality of life, Ageing, Medical imaging

The nationally-comprised study population includes 150 liver cirrhosis patients aged 18 and up, with no liver transplant history or contraindications to performing an MRI examination, enrolled from one of three Swedish liver care clinics located in Linköping, Eksjö, or Jönköping.

Key Points: 
  • The nationally-comprised study population includes 150 liver cirrhosis patients aged 18 and up, with no liver transplant history or contraindications to performing an MRI examination, enrolled from one of three Swedish liver care clinics located in Linköping, Eksjö, or Jönköping.
  • Over a duration of 2 years, patients will be assessed every 6 months with a comprehensive clinical examination and a whole-body MRI examination.
  • AMRA’s muscle volume (MV) and muscle fat infiltration (MFI) measures have previously been shown to independently predict all-cause mortality 1 and comorbid vulnerability 2 in patients with fatty liver disease.
  • The full manuscript detailing the ACCESS-ESLD study design and objectives was recently published in the journal BMC Gastroenterology in late 2023.

MUSCLE CULTIVATION STARTUP PROFUSE-TECHNOLOGY WELCOMES RENOWNED TECHNION PROFESSOR TO ITS SCIENTIFIC ADVISORY BOARD

Retrieved on: 
måndag, april 22, 2024
Diabetes, Biomedical engineering, Weight loss, Research, Duchenne, Weizmann Institute of Science, Obesity, Biomedicine, Therapy, Cachexia, Patient, Tissue engineering, Regenerative medicine, Sarcopenia, Duchenne muscular dystrophy, Faculty, Ageing, Biotechnology, Pharmaceutical industry

YOKNEAM, Israel, April 22, 2024 /PRNewswire/ -- ProFuse Technology expands its scope as a muscle cultivation startup aiming to enhance patient outcomes by improving treatments for muscle associated diseases and muscle regeneration. The company has appointed Professor Shulamit Levenberg of the Technion Faculty of Biomedical Engineering to its Scientific Advisory Board, to support its effort towards life science applications.

Key Points: 
  • YOKNEAM, Israel, April 22, 2024 /PRNewswire/ -- ProFuse Technology expands its scope as a muscle cultivation startup aiming to enhance patient outcomes by improving treatments for muscle associated diseases and muscle regeneration.
  • The company has appointed Professor Shulamit Levenberg of the Technion Faculty of Biomedical Engineering to its Scientific Advisory Board, to support its effort towards life science applications.
  • She has joined ProFuse Technology's Scientific Advisory Board to bolster the company's effort to develop materials and methodologies for muscle regeneration and maintenance.
  • We are thrilled to welcome Professor Levenberg's to our Scientific Advisory Board, in order to bolster our pioneering innovative approaches towards muscle regeneration and maintenance."

Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update

Retrieved on: 
måndag, mars 25, 2024
ART, Research, Depression, Neuropathic pain, Argyreia nervosa, Weight gain, Cachexia, Anxiety, Cancer, IND, Investment, Safety, Pain, FDA, Cannabidiol, Pharmaceutical industry

SOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the fiscal year ended December 31, 2023 and provided a business update.

Key Points: 
  • SOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological conditions, today reported financial and operating results for the fiscal year ended December 31, 2023 and provided a business update.
  • “We made substantial progress on multiple programs last year,” commented Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences.
  • Cash and Investments: Cash and investments totalled $10.4 million as of December 31, 2023.
  • R&D Expenses: Research and development expenses were $5.7 million for the year ended December 31, 2023, compared to $4.3 million for the same period in 2022.

A Global Milestone in Innovative Pancreatic Cancer Therapy

Retrieved on: 
torsdag, mars 7, 2024
Bangladesh Technical Education Board, Cancer, Cachexia, Toxicity, Anemia, Multimedia, Cell proliferation, NIH, Molecular biology, Pancreatic cancer, FDA, Quality of life, Animal, Drug development, Growth, Gallbladder, Metastasis, Nausea, Peripheral neuropathy, Argyreia nervosa, Lung, Breast, Stomach, Life expectancy, Leukemia, Patient, Paclitaxel, Survival, Diagnosis, Research, BGX, Biochemistry, Pharmaceutical industry

TAIPEI, March 6, 2024 /PRNewswire/ -- BioGate Precision Medicine Corp., a member of Powerchip Group, held a press conference today to unveil an innovative breakthrough in pancreatic cancer drug development. Dr. Frank Huang, Chairman and CEO of BioGate, revealed that BioGate through in-house R&D has created a targeted therapy biologic, BGX. This was achieved by developing multi-platform technology combining biochemistry, immunology, and molecular biology. Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates. This achievement represents a major global milestone in pancreatic cancer treatment. BioGate also announced its plan to apply for TFDA Phase I clinical trials and to seek approval from the U.S. FDA, offering hope and improved care for pancreatic cancer patients in Taiwan region as well as worldwide.

Key Points: 
  • Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy developed in-house by BioGate.
  • Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates.
  • This achievement represents a major global milestone in pancreatic cancer treatment.
  • In studies of animals implanted with human cancer cells, BGX successfully inhibited the growth and spread of pancreatic cancer cells and prolonged survival rates.

A Global Milestone in Innovative Pancreatic Cancer Therapy

Retrieved on: 
torsdag, mars 7, 2024
Bangladesh Technical Education Board, Cancer, Cachexia, Toxicity, Anemia, Cell proliferation, NIH, Molecular biology, Pancreatic cancer, FDA, Quality of life, Animal, Drug development, Growth, Gallbladder, Metastasis, Nausea, Peripheral neuropathy, Argyreia nervosa, Lung, Breast, Stomach, Life expectancy, Leukemia, Patient, Paclitaxel, Survival, Diagnosis, Research, BGX, Biochemistry, Pharmaceutical industry

TAIPEI, March 7, 2024 /PRNewswire/ -- BioGate Precision Medicine Corp., a member of Powerchip Group, held a press conference today to unveil an innovative breakthrough in pancreatic cancer drug development. Dr. Frank Huang, Chairman and CEO of BioGate, revealed that BioGate through in-house R&D has created a targeted therapy biologic, BGX. This was achieved by developing multi-platform technology combining biochemistry, immunology, and molecular biology. Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates. This achievement represents a major global milestone in pancreatic cancer treatment. BioGate also announced its plan to apply for TFDA Phase I clinical trials and to seek approval from the U.S. FDA, offering hope and improved care for pancreatic cancer patients in Taiwan region as well as worldwide.

Key Points: 
  • Suppression of pancreatic cancer and increased survival rates in animals implanted with human pancreatic cancer cells when treated with biologic agent BGX, a proprietary targeted therapy developed in-house by BioGate.
  • Studies of animals implanted with human pancreatic cancer cells confirm BGX's efficacy in inhibiting tumor growth and antiproliferation in metastasis, while extending survival rates.
  • This achievement represents a major global milestone in pancreatic cancer treatment.
  • In studies of animals implanted with human cancer cells, BGX successfully inhibited the growth and spread of pancreatic cancer cells and prolonged survival rates.

For cancer patients, maintaining muscle is vital to health and treatment, but staying strong is complicated

Retrieved on: 
torsdag, januari 4, 2024
Patient, Cachexia, Body composition, Walking, Quality of life, Skeletal muscle, Skeleton, Myopathy, Metabolism, Movement, Prognosis, Research, Depression, Weight loss, Diet, Fatigue, Disease, Neoplasm, Exercise, Heart, Cancer, Atrophy, Anxiety, Mental health, Death, Appetite, Obesity, Gardening, Facial muscles, Inflammation, Human, Body image, Rhabdomyolysis, Dietary supplement

Nearly one-third of cancer patients die from a side-effect you’ve likely never heard of: cancer cachexia.

Key Points: 
  • Nearly one-third of cancer patients die from a side-effect you’ve likely never heard of: cancer cachexia.
  • With cachexia, a patient loses a significant amount of weight due to their disease, with considerable losses of muscle mass.

What exactly is cancer cachexia?

  • Cancer cachexia is an unintentional loss of body weight that mainly affects muscle.
  • It is diagnosed when a cancer patient loses more than five per cent of their body weight over six months.
  • Cancer cachexia is complex, and is likely caused by many factors working together.
  • Inflammation from cancer or chemotherapy, reduced appetite and food intake, or even specific interactions between a tumour and muscle could all play a role.

The impact of cachexia on patients

  • Cancer cachexia can have a significant impact on a patient’s quality of life and prognosis.
  • Patients with cachexia tend to have lower treatment tolerances than those of healthy body composition.
  • Cachexia patients report struggling with body image, loss of independence and becoming a burden to their loved ones.

Treating cachexia


Unfortunately, Canada lacks standardized options for treating patients with cancer cachexia. Research suggests that treating cachexia should use a multi-targeted approach. Nutritional interventions are essential for combating cachexia and should be started as soon as possible with consultation from a registered dietitian.

  • Exercise could be a very powerful tool to treat cachexia.
  • Studies on pharmacological compounds to treat cachexia have produced varied results, and many are still in early phase clinical trials.

Diagnosing and detecting cachexia

  • Perhaps the biggest limitation in treating cachexia is detecting it early enough to intervene.
  • Diagnosing cachexia is largely based on weight-related measures.
  • Integrating strength assessments as well as body composition scans across all points of the cancer journey could help capture the whole picture of cachexia development and progression.

Where to go from here

  • The sooner it is detected, the better chance there is to manage it.
  • Management should involve a multi-disciplinary team that can help with diet, exercise and psycho-social aspects of the condition.
  • It will likely be years before these reach the clinic, so early interventions with nutrition, exercise and regular monitoring are critical.


Meghan McCue receives funding from the Canadian Cancer Society and the Canadian Partnership Against Cancer.

EOM Pharmaceutical Holdings Provides an Update on its Lead Drug Candidate EOM613

Retrieved on: 
tisdag, november 7, 2023
IND, Glossary, Incidence, Gastrointestinal tract, Patent, Korea Disease Control and Prevention Agency, Fungal infection, Cachexia, Toxicology, OTC, Prevalence, MD, Doctor of Philosophy, Ulcerative colitis, Inflammatory bowel disease, Crohn's disease, CDC, Disease, Clinical trial, COVID-19, Risk, EOM, Effectiveness, IBD, Patent pending, Patient, Pharmaceutical industry, Vaccine, AIDS

MONTVALE, N.J., Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613.

Key Points: 
  • MONTVALE, N.J., Nov. 7, 2023 /PRNewswire/ -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) ("EOM") today provides an update on its clinical program for its lead drug candidate EOM613.
  • In light of these clinical trial results, the company is currently preparing to initiate an EOM613 clinical program in Crohn's disease.
  • "In previous clinical trials in AIDS, cancer cachexia and COVID-19 patients, EOM613 was demonstrated to be well-tolerated, even in very sick patients.
  • "EOM's priority is to initiate a clinical program in inflammatory bowel disease as soon as possible," added Irach B. Taraporewala, PhD, Chief Executive Officer of EOM.